Key statistics dashboard for Pliant Therapeutics, Inc. (PLRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
Stock Data
| Price | $1.07 |
| Market Cap | $66M |
| Enterprise Value | $70.1M |
| Beta | 1.25 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.75 |
| Price / Book | 0.47 |
| P/S | 0.00 |
| EV/EBITDA | -0.80 |
| EV/Sales | 0.00 |
| EV/FCF | -0.99 |
| P/FCF | -0.98 |
| Earnings Yield | -139.30% |
| FCF Yield | -107.00% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -53.22% |
| Return on Assets | -48.60% |
| Return on Invested Capital | -55.49% |
| Return on Capital Employed | -56.22% |
Financial Health
| Current Ratio | 9.90 |
| Quick Ratio | 9.90 |
| Cash Ratio | 1.51 |
| Debt / Equity | 0.20 |
| Debt / Assets | 15.14% |
| Net Debt / EBITDA | -0.04 |
| Interest Coverage | -102.50 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.37 |
| Cash per share | 2.55 |
| FCF per share | -1.14 |
| Tangible Book Value per share | 2.37 |
| Dividend per share | 0.00 |
Related companies: ADVM · ARTV · CLNN · COYA · GUTS · MGNX · OVID
Explore sector: Healthcare · Biotechnology
More sections of PLRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks